Aprea Therapeutics (APRE) News Today $2.92 -0.09 (-2.99%) (As of 12:30 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Aprea Therapeutics' (APRE) Buy Rating Reiterated at HC WainwrightNovember 21 at 2:13 AM | americanbankingnews.comAprea Therapeutics: Buy Rating Driven by Clinical Progress and Financial StabilityNovember 18 at 7:50 PM | markets.businessinsider.comShort Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Increases By 90.8%November 14, 2024 | americanbankingnews.comAprea Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 11, 2024 | finance.yahoo.comBuy Recommendation for Aprea Therapeutics Based on Promising Clinical Progress and Strategic Financial PositioningNovember 9, 2024 | markets.businessinsider.comAprea Therapeutics Reports Q3 Financials and Advances in Clinical TrialsNovember 9, 2024 | msn.comAprea Therapeutics reports Q3 EPS (64c) vs (86c) last yearNovember 8, 2024 | markets.businessinsider.comAprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International SymposiumOctober 26, 2024 | msn.comAprea Therapeutics, Inc. (NASDAQ:APRE) Director Sells $29,595.96 in StockOctober 26, 2024 | insidertrades.comPromising Safety and Financial Strength Propel Buy Rating for Aprea TherapeuticsOctober 25, 2024 | markets.businessinsider.comInsider Spends US$132k Buying More Shares In Aprea TherapeuticsOctober 23, 2024 | finance.yahoo.comAprea Therapeutics presents preliminary results on APR-1051October 23, 2024 | markets.businessinsider.comOptimistic Buy Recommendation for Aprea Therapeutics: Promising Developments in WEE1 Kinase InhibitorOctober 23, 2024 | markets.businessinsider.comAprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsOctober 23, 2024 | globenewswire.comAprea Therapeutics, Inc. (NASDAQ:APRE) Director Buys $131,700.00 in StockOctober 18, 2024 | insidertrades.comAprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual SummitOctober 16, 2024 | msn.comInsider Buying: Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Buys 10,000 Shares of StockOctober 16, 2024 | insidertrades.comAprea Therapeutics to Present at Maxim 2024 Healthcare Virtual SummitOctober 14, 2024 | globenewswire.comAprea Therapeutics to Showcase Oncology Advances at Barcelona SymposiumOctober 12, 2024 | msn.comAprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsOctober 10, 2024 | globenewswire.comAprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical DevelopmentOctober 9, 2024 | globenewswire.comAprea Therapeutics to Present at Lytham Partners Fall Investor ConferenceSeptember 26, 2024 | msn.comAprea Therapeutics to Present at the Life Sciences Investor Forum on September 19September 12, 2024 | finance.yahoo.comDoylestown Cancer Pharma Moves Closer to Starting Clinical Testing on Its 3rd Experimental Cancer TreatmentSeptember 10, 2024 | msn.comUPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceSeptember 9, 2024 | globenewswire.comAprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceSeptember 9, 2024 | globenewswire.comAprea Therapeutics to Present at H.C. Wainwright Investment ConferenceAugust 29, 2024 | msn.comAprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceAugust 28, 2024 | globenewswire.comActor John Aprea Had a Long Career in Hollywood: A Look Back at His Life After His Death at Age 83August 19, 2024 | yahoo.comJohn Aprea, The ‘Godfather II’ and ‘Full House’ Actor, Dies At 83August 19, 2024 | forbes.comJohn Aprea, Another World And Knots Landing Star, Died At 83August 19, 2024 | yahoo.comJohn Aprea Dies: ‘The Godfather Part II’ & ‘Full House’ Actor Was 83August 18, 2024 | msn.comJohn Aprea, ‘Godfather Part II’ and ‘Full House’ Actor, Dies at 83August 18, 2024 | msn.comJohn Aprea, ‘The Godfather Part II’ Actor, Dies at 83August 18, 2024 | msn.comJohn Aprea, Actor in ‘The Godfather Part II’ and ‘Full House,’ Dies at 83August 18, 2024 | msn.comJohn Aprea Dies: ‘Another World’ & ‘Full House’ Star Was 83August 18, 2024 | msn.comJohn Aprea, "The Godfather Part II" and "Full House" actor, dies at 83August 18, 2024 | msn.comAprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical TrialsAugust 14, 2024 | msn.comBuy Rating Justified by Aprea Therapeutics’ Financial Health and Innovative Clinical TrialsAugust 13, 2024 | markets.businessinsider.comAprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 12, 2024 | globenewswire.comAprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024June 21, 2024 | globenewswire.comAprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051June 17, 2024 | globenewswire.comAprea Therapeutics Advances Cancer Treatment Trial to Higher Dose LevelMay 29, 2024 | msn.comAprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical TrialMay 28, 2024 | globenewswire.comAprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug TrialsMay 15, 2024 | msn.comBuy Rating Affirmed: Aprea Therapeutics’ Financial and Clinical ProgressMay 14, 2024 | markets.businessinsider.comAPRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024May 14, 2024 | investorplace.comAprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business UpdateMay 14, 2024 | globenewswire.comAprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare ConferenceMay 13, 2024 | globenewswire.comAprea Therapeutics Appoints Mirza As CMOMay 2, 2024 | markets.businessinsider.com Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! APRE Media Mentions By Week APRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APRE News Sentiment▼0.560.47▲Average Medical News Sentiment APRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APRE Articles This Week▼51▲APRE Articles Average Week Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CLRB News Today INCR News Today CELU News Today OPTN News Today ALRN News Today CRVO News Today ATRA News Today XFOR News Today MURA News Today ENTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APRE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APRE Stock Alerts